| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | microtubule cytoskeleton organization involved in establishment of planar polarity | 4.23e-06 | 3 | 25 | 2 | GO:0090176 | |
| GeneOntologyBiologicalProcess | establishment of planar polarity | 2.02e-05 | 44 | 25 | 3 | GO:0001736 | |
| GeneOntologyBiologicalProcess | establishment of tissue polarity | 2.16e-05 | 45 | 25 | 3 | GO:0007164 | |
| GeneOntologyBiologicalProcess | regulation of axonogenesis | 7.90e-05 | 192 | 25 | 4 | GO:0050770 | |
| GeneOntologyBiologicalProcess | regulation of synaptic vesicle clustering | 9.24e-05 | 12 | 25 | 2 | GO:2000807 | |
| GeneOntologyBiologicalProcess | morphogenesis of a polarized epithelium | 9.25e-05 | 73 | 25 | 3 | GO:0001738 | |
| GeneOntologyBiologicalProcess | synaptic vesicle clustering | 3.21e-04 | 22 | 25 | 2 | GO:0097091 | |
| GeneOntologyBiologicalProcess | plasma membrane bounded cell projection morphogenesis | 3.56e-04 | 819 | 25 | 6 | GO:0120039 | |
| GeneOntologyBiologicalProcess | cell projection morphogenesis | 3.73e-04 | 826 | 25 | 6 | GO:0048858 | |
| GeneOntologyBiologicalProcess | regulation of plasma membrane bounded cell projection organization | 4.24e-04 | 846 | 25 | 6 | GO:0120035 | |
| GeneOntologyBiologicalProcess | regulation of cell projection organization | 4.71e-04 | 863 | 25 | 6 | GO:0031344 | |
| GeneOntologyBiologicalProcess | axonogenesis | 5.15e-04 | 566 | 25 | 5 | GO:0007409 | |
| GeneOntologyBiologicalProcess | telencephalon development | 6.38e-04 | 332 | 25 | 4 | GO:0021537 | |
| Domain | SEMA | 7.19e-04 | 31 | 24 | 2 | PS51004 | |
| Domain | Sema | 7.19e-04 | 31 | 24 | 2 | SM00630 | |
| Domain | Semap_dom | 7.19e-04 | 31 | 24 | 2 | IPR001627 | |
| Domain | Sema | 7.19e-04 | 31 | 24 | 2 | PF01403 | |
| Domain | Plexin_repeat | 7.67e-04 | 32 | 24 | 2 | IPR002165 | |
| Domain | PSI | 7.67e-04 | 32 | 24 | 2 | PF01437 | |
| Domain | PSI | 1.45e-03 | 44 | 24 | 2 | IPR016201 | |
| Domain | PSI | 1.58e-03 | 46 | 24 | 2 | SM00423 | |
| Domain | Ca/CaM-dep_Ca-dep_prot_Kinase | 3.52e-03 | 69 | 24 | 2 | IPR020636 | |
| Domain | ARM-type_fold | 9.04e-03 | 339 | 24 | 3 | IPR016024 | |
| Domain | Ser/Thr_kinase_AS | 1.04e-02 | 357 | 24 | 3 | IPR008271 | |
| Domain | S_TKc | 1.06e-02 | 359 | 24 | 3 | SM00220 | |
| Domain | PROTEIN_KINASE_ST | 1.08e-02 | 362 | 24 | 3 | PS00108 | |
| Domain | Protein_kinase_ATP_BS | 1.22e-02 | 379 | 24 | 3 | IPR017441 | |
| Domain | Pkinase | 1.24e-02 | 381 | 24 | 3 | PF00069 | |
| Domain | PROTEIN_KINASE_ATP | 2.03e-02 | 459 | 24 | 3 | PS00107 | |
| Pubmed | 4.96e-07 | 2 | 25 | 2 | 16630837 | ||
| Pubmed | Investigating the regulation of brain-specific kinases 1 and 2 by phosphorylation. | 4.96e-07 | 2 | 25 | 2 | 18339622 | |
| Pubmed | Neurochemical correlates of synapse density in a Huntington's disease mouse model. | 4.96e-07 | 2 | 25 | 2 | 36272099 | |
| Pubmed | Isozyme-Specific Role of SAD-A in Neuronal Migration During Development of Cerebral Cortex. | 4.96e-07 | 2 | 25 | 2 | 30307479 | |
| Pubmed | Microtubule stabilization specifies initial neuronal polarization. | 1.49e-06 | 3 | 25 | 2 | 18268107 | |
| Pubmed | 1.49e-06 | 3 | 25 | 2 | 22669945 | ||
| Pubmed | 1.49e-06 | 3 | 25 | 2 | 20026642 | ||
| Pubmed | 2.97e-06 | 4 | 25 | 2 | 18794346 | ||
| Pubmed | 2.97e-06 | 4 | 25 | 2 | 24951540 | ||
| Pubmed | 4.13e-06 | 152 | 25 | 4 | 34299191 | ||
| Pubmed | Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function. | 4.95e-06 | 5 | 25 | 2 | 15150265 | |
| Pubmed | 4.95e-06 | 5 | 25 | 2 | 18854318 | ||
| Pubmed | Retrograde semaphorin signaling regulates synapse elimination in the developing mouse brain. | 4.95e-06 | 5 | 25 | 2 | 24831527 | |
| Pubmed | Mammalian SAD kinases are required for neuronal polarization. | 7.43e-06 | 6 | 25 | 2 | 15705853 | |
| Pubmed | 7.43e-06 | 6 | 25 | 2 | 24395778 | ||
| Pubmed | Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. | 7.43e-06 | 6 | 25 | 2 | 21985311 | |
| Pubmed | 7.43e-06 | 6 | 25 | 2 | 25086610 | ||
| Pubmed | Tropomodulin isoforms regulate thin filament pointed-end capping and skeletal muscle physiology. | 2.22e-05 | 10 | 25 | 2 | 20368620 | |
| Pubmed | Molecular diversity of myofibrillar proteins: gene regulation and functional significance. | 3.26e-05 | 12 | 25 | 2 | 8618961 | |
| Pubmed | 3.26e-05 | 12 | 25 | 2 | 23275438 | ||
| Pubmed | 3.85e-05 | 13 | 25 | 2 | 10520995 | ||
| Pubmed | 3.85e-05 | 13 | 25 | 2 | 29698519 | ||
| Pubmed | 4.49e-05 | 14 | 25 | 2 | 21525298 | ||
| Pubmed | LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. | 5.18e-05 | 15 | 25 | 2 | 14976552 | |
| Pubmed | LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. | 8.42e-05 | 19 | 25 | 2 | 17482548 | |
| Pubmed | Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. | 9.35e-05 | 20 | 25 | 2 | 18227155 | |
| Pubmed | A dual-activity topoisomerase complex regulates mRNA translation and turnover. | 1.07e-04 | 1105 | 25 | 6 | 35748872 | |
| Pubmed | 1.24e-04 | 23 | 25 | 2 | 23790753 | ||
| Pubmed | A semaphorin code defines subpopulations of spinal motor neurons during mouse development. | 1.36e-04 | 24 | 25 | 2 | 15869472 | |
| Pubmed | Semaphorin heterodimerization in cis regulates membrane targeting and neocortical wiring. | 1.60e-04 | 26 | 25 | 2 | 39152101 | |
| Pubmed | 1.85e-04 | 28 | 25 | 2 | 18617019 | ||
| Pubmed | 1.85e-04 | 28 | 25 | 2 | 17951031 | ||
| Pubmed | Ankyrin repeats of ANKRA2 recognize a PxLPxL motif on the 3M syndrome protein CCDC8. | 1.85e-04 | 28 | 25 | 2 | 25752541 | |
| Pubmed | 14-3-3 cooperates with LKB1 to regulate the activity and localization of QSK and SIK. | 2.13e-04 | 30 | 25 | 2 | 16306228 | |
| Pubmed | STK11 is required for the normal program of ciliated cell differentiation in airways. | 2.28e-04 | 31 | 25 | 2 | 31636950 | |
| Pubmed | Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice. | 3.62e-04 | 39 | 25 | 2 | 24703692 | |
| Pubmed | 3.80e-04 | 40 | 25 | 2 | 28386764 | ||
| Pubmed | A High-Density Map for Navigating the Human Polycomb Complexome. | 4.04e-04 | 495 | 25 | 4 | 27705803 | |
| Pubmed | 5.95e-04 | 50 | 25 | 2 | 23272104 | ||
| Pubmed | 5.95e-04 | 50 | 25 | 2 | 37974198 | ||
| Pubmed | 6.43e-04 | 52 | 25 | 2 | 26633812 | ||
| Interaction | HSPH1 interactions | 1.44e-05 | 448 | 25 | 6 | int:HSPH1 | |
| GeneFamily | Immunoglobulin like domain containing | 1.55e-02 | 193 | 18 | 2 | 594 | |
| ToppCell | mild_COVID-19_(asymptomatic)-NK_CD56bright|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 2.01e-08 | 151 | 25 | 5 | 2470162f4b56bc505db166a6eb0fa54847759df8 | |
| ToppCell | mild_COVID-19_(asymptomatic)-NK_CD56bright|World / disease group, cell group and cell class (v2) | 1.54e-06 | 153 | 25 | 4 | aff5c8ab1fb4ebc324cec02cf562b7484bb10db8 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c02-NCAM1|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.98e-06 | 163 | 25 | 4 | 1c014e373667be290d7fb5d24c06c6f313ac8fa3 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-plasmacytoid_dendritic_cell-DC_c4-LILRA4|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.87e-05 | 143 | 25 | 3 | d0ed8c25da1327085e042c2e03cb7503e2c52ce0 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic-plasmacytoid_dendritic_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.87e-05 | 143 | 25 | 3 | 8900b92a24289204b9ec7baccc11594fec7694f1 | |
| ToppCell | 343B-Myeloid-Dendritic-pDC|343B / Donor, Lineage, Cell class and subclass (all cells) | 8.89e-05 | 156 | 25 | 3 | 547e2debfc09c07c049a880dded5fda7dd53e156 | |
| ToppCell | COVID_non-vent-Lymphocytic-Dendritic-pDC|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 9.58e-05 | 160 | 25 | 3 | 61f4cb4eb4313d8318aadbb99595a6cb7fd919f7 | |
| ToppCell | COVID_non-vent-Lymphocytic-Dendritic|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 9.58e-05 | 160 | 25 | 3 | 34b4f710cfcb6ec370b8b074f3cbfe272f392cec | |
| ToppCell | Bronchial-10x5prime-Stromal-Schwann|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 9.94e-05 | 162 | 25 | 3 | afffecc6c504930554aafc12c5bffa53e3c5b016 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.15e-04 | 170 | 25 | 3 | 92e765ae0d3adb38d3b22fddb873fd5ccad3fd44 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.15e-04 | 170 | 25 | 3 | 9f8b215caa1afa3cd7104c06fca7cfd790640f66 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs-Plasmacytoid_DCs_L.1.5.1.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.15e-04 | 170 | 25 | 3 | b49f7c8a27078de2137ed04f74cfee30729cfa5e | |
| ToppCell | mild_COVID-19-pDC|World / disease group, cell group and cell class (v2) | 1.19e-04 | 172 | 25 | 3 | dab2f1a05c7df58d9387b13271b3f1f1583f9ac3 | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Hematopoietic-T_cells-ILCP|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.23e-04 | 174 | 25 | 3 | c0204a0d0a979a489e8d30dc5396e99da14c119c | |
| ToppCell | CTRL-Lymphoid-pDC|Lymphoid / Disease state, Lineage and Cell class | 1.23e-04 | 174 | 25 | 3 | ff4315e9fad198cc323fc987deb8652da137cf98 | |
| ToppCell | IIF-Myeloid-pDC|IIF / Disease, Lineage and Cell Type | 1.25e-04 | 175 | 25 | 3 | 35cfb7d0b88678ff5b83ad6e19dbc15a908a3fcc | |
| ToppCell | mild_COVID-19-pDC|mild_COVID-19 / disease group, cell group and cell class (v2) | 1.25e-04 | 175 | 25 | 3 | b87f279a7519710146c49d6acccb0adedc195965 | |
| ToppCell | (1)_Control_(PBS)-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)|(1)_Control_(PBS) / Stress and Cell class | 1.29e-04 | 177 | 25 | 3 | d9e5ac5b8949a77e88e8094079167e4cf2c1bbd1 | |
| ToppCell | Control-Myeloid-pDC|Control / Disease state, Lineage and Cell class | 1.29e-04 | 177 | 25 | 3 | 3940663bb5b45b2ca9f772550380a516c53e410b | |
| ToppCell | Control-Myeloid-pDC|Myeloid / Disease state, Lineage and Cell class | 1.29e-04 | 177 | 25 | 3 | e82115bfc32c7b689460fbc5caeb983c1aabe30f | |
| ToppCell | Severe-B_intermediate-10|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.31e-04 | 178 | 25 | 3 | b7374a97c51239782bed658381a02cb1b3d9bf66 | |
| ToppCell | Healthy/Control-pDC|Healthy/Control / Disease group and Cell class | 1.31e-04 | 178 | 25 | 3 | 072b346c6bbd63f00efaceda486400a669b3ec48 | |
| ToppCell | Control-Myeloid-pDC|World / Disease state, Lineage and Cell class | 1.31e-04 | 178 | 25 | 3 | 20ef63d925e67ddd5955832312ca8574a6f838a4 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Endothelial|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.36e-04 | 180 | 25 | 3 | f9b7d5eb7b6ea72253c89bdc351ad2b4a53f7d8e | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Endothelial-endothelial_cell|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.36e-04 | 180 | 25 | 3 | 53db6032eda0e590ae7e01c9c3b472785ea6782f | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m-Endothelial-nan|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.36e-04 | 180 | 25 | 3 | 28bc10b9d0e4430b952260014d8a6ff337860ac6 | |
| ToppCell | 3'_v3-Lung-Myeloid_Dendritic-pDC|Lung / Manually curated celltypes from each tissue | 1.38e-04 | 181 | 25 | 3 | 3d7f089fb434fbc989f1fa159e22133ae00b2487 | |
| ToppCell | systemic_lupus_erythematosus-treated-Myeloid-plasmacytoid_dendritic_cell-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.40e-04 | 182 | 25 | 3 | 9bbe8062aa562dc3b9c299581faf6ebbcb72a9f7 | |
| ToppCell | systemic_lupus_erythematosus-treated-Myeloid-plasmacytoid_dendritic_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.40e-04 | 182 | 25 | 3 | 4602a98df7045e2c70b7560abfba9b444fbd5d30 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Dendritic-plasmacytoid_dendritic_cell|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.43e-04 | 183 | 25 | 3 | df6fd0927b6e4cf9a1583969a68096e4bccfbace | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Myeloid-Dendritic-plasmacytoid_dendritic_cell-DC_c4-LILRA4|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.43e-04 | 183 | 25 | 3 | 3b123571e10c132227aff65648b4b3c6acb4bd00 | |
| ToppCell | systemic_lupus_erythematosus-managed-Myeloid-plasmacytoid_dendritic_cell-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.47e-04 | 185 | 25 | 3 | cc5152d3055375172bdf84f442b233c8fbd422b3 | |
| ToppCell | normal-na-Myeloid-plasmacytoid_dendritic_cell-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 1.47e-04 | 185 | 25 | 3 | 3091870a5bf8ecb963e560b47c8502bae367416c | |
| ToppCell | Healthy_donor-pDC|Healthy_donor / disease group, cell group and cell class (v2) | 1.47e-04 | 185 | 25 | 3 | 7fbb55cbdb39bdecb6063c8ba9776ab06c2666e8 | |
| ToppCell | (1)_Control_(PBS)-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)|World / Stress and Cell class | 1.47e-04 | 185 | 25 | 3 | b8cd94cf18308b514fc61557550225794ffd2860 | |
| ToppCell | PBMC-Severe-Myeloid-pDC-pDC|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.50e-04 | 186 | 25 | 3 | b70cd94c651b56dcf2e55554533a5f1130845390 | |
| ToppCell | PBMC-Severe-Myeloid-pDC-pDC-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.50e-04 | 186 | 25 | 3 | 31df1eafa3010bc1be6fc4d4689f1393d69b6b13 | |
| ToppCell | PBMC-Severe-Myeloid-pDC|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.50e-04 | 186 | 25 | 3 | eaa431ccd4cdd36fe06a44987603ec9979025aa8 | |
| ToppCell | COVID-19_Severe-Myeloid-pDC|COVID-19_Severe / Disease group, lineage and cell class | 1.50e-04 | 186 | 25 | 3 | 3db5ed69d49e5d79f990aca0295ddce4c297a05c | |
| ToppCell | PBMC-Severe-Myeloid-pDC|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.50e-04 | 186 | 25 | 3 | b95be984e308d4f9061274a35995ec558d434e74 | |
| ToppCell | PBMC-Severe-Myeloid-pDC-pDC-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.50e-04 | 186 | 25 | 3 | 8f7949740286f64e034d1eb533ebc2c6f71ae966 | |
| ToppCell | PBMC-Severe-Myeloid-pDC-pDC|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.50e-04 | 186 | 25 | 3 | 95c7318e521fb6aa02e244b1e81e6b2a62107756 | |
| ToppCell | Healthy_donor-pDC|World / disease group, cell group and cell class (v2) | 1.52e-04 | 187 | 25 | 3 | aa2cc54487d3c5045ac0c93560944c5a55878e27 | |
| ToppCell | COVID-19_Severe-pDC-|COVID-19_Severe / Disease condition and Cell class | 1.54e-04 | 188 | 25 | 3 | 9fd1116e31a05554850b8ed3c005ea660dfbd51c | |
| ToppCell | PBMC-Mild-Myeloid-pDC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.54e-04 | 188 | 25 | 3 | de6a270b6e4fe09c39a52c296632d86ada98465b | |
| ToppCell | PBMC-Mild-Myeloid-pDC-pDC|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.54e-04 | 188 | 25 | 3 | 89411c4db3df5e1dc36cf8af4ffcc0abbecbe4df | |
| ToppCell | COVID-19_Mild-pDC|COVID-19_Mild / Disease condition and Cell class | 1.54e-04 | 188 | 25 | 3 | 62d33d2990d4a2d32bd0863147e47f656df1966e | |
| ToppCell | PBMC-Mild-Myeloid-pDC-pDC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.54e-04 | 188 | 25 | 3 | 879054b780378ae05be68e597c77c931bf0ade03 | |
| ToppCell | COVID-19_Mild-pDC-|COVID-19_Mild / Disease condition and Cell class | 1.54e-04 | 188 | 25 | 3 | a75c2cf2f8dae343c13aaa66b637658b935ed10a | |
| ToppCell | COVID-19_Severe-pDC|COVID-19_Severe / Disease condition and Cell class | 1.54e-04 | 188 | 25 | 3 | 475008f45673b42b75ef231c2df91f8b9adc9201 | |
| ToppCell | PBMC-Mild-Myeloid-pDC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.57e-04 | 189 | 25 | 3 | 209cae68d78c8f72479b169e27c3ff7e143adece | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Dendritic-pDC|lymph-node_spleen / Manually curated celltypes from each tissue | 1.57e-04 | 189 | 25 | 3 | 6c2ace61a7d62bcf7e76b73e2da8b722d03e713b | |
| ToppCell | PBMC-Mild-Myeloid-pDC-pDC-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.57e-04 | 189 | 25 | 3 | a9ad1fb12304541f909dd0eeac9b9eb28c31fd41 | |
| ToppCell | COVID-19_Mild-Myeloid-pDC|COVID-19_Mild / Disease group, lineage and cell class | 1.57e-04 | 189 | 25 | 3 | c6cfd6aa21c19f2c62d80218bbc924e14e82aada | |
| ToppCell | PBMC-Mild-Myeloid-pDC-pDC|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.57e-04 | 189 | 25 | 3 | 98ca646231fbd5f29827c2dd31ac4503026bad7d | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW09-Neuronal-Neuron|GW09 / Sample Type, Dataset, Time_group, and Cell type. | 1.57e-04 | 189 | 25 | 3 | 3717d1148e26ac78a26aea0ca1dbfbb9d3668877 | |
| ToppCell | 3'_v3-bone_marrow-Myeloid_Dendritic-pDC|bone_marrow / Manually curated celltypes from each tissue | 1.59e-04 | 190 | 25 | 3 | dde0e34f6a06cdbbb65c86472360c09f0279a572 | |
| ToppCell | 3'_v3-bone_marrow-Myeloid_Dendritic|bone_marrow / Manually curated celltypes from each tissue | 1.59e-04 | 190 | 25 | 3 | 6892c603037b61ef88d6ca01b7592dc0d347d63b | |
| ToppCell | 3'_v3-lymph-node_spleen-Myeloid_Dendritic|lymph-node_spleen / Manually curated celltypes from each tissue | 1.62e-04 | 191 | 25 | 3 | c3ff4342e0eea1e1f071b1fbca14a6dd4df0c696 | |
| ToppCell | systemic_lupus_erythematosus-managed-Myeloid-plasmacytoid_dendritic_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.62e-04 | 191 | 25 | 3 | 8c487704cbbb5eeff54e8c6fb6fffa1472b5351f | |
| ToppCell | systemic_lupus_erythematosus-managed-Myeloid-plasmacytoid_dendritic_cell-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 1.62e-04 | 191 | 25 | 3 | 78d523f562d32fc408a20d99b0c61cc103241bc0 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_chondroblast_(18)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 1.64e-04 | 192 | 25 | 3 | d0649410cf5eacdb0c1dce70e37c7473ef5fddfa | |
| ToppCell | Healthy-B_intermediate|Healthy / disease group, cell group and cell class | 1.69e-04 | 194 | 25 | 3 | aabee48bf689367edae2079b4b90d253715f1097 | |
| ToppCell | proximal-3-Endothelial-Vein|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.72e-04 | 195 | 25 | 3 | c81eb541c15b866f9b6ca6a5f1751c5f1243f4fb | |
| ToppCell | proximal-Endothelial-Vein|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.72e-04 | 195 | 25 | 3 | 0aebdd635a956dd2367883c1cf73d73ce9790635 | |
| ToppCell | Biopsy_Control_(H.)-Immune-pDCs|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 1.72e-04 | 195 | 25 | 3 | 47d139215f0b51f5ea9b5fb09b1100e320e3f1e2 | |
| ToppCell | proximal-Endothelial-Vein-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.72e-04 | 195 | 25 | 3 | df00f94facc5d6107aac83cef3c64fefc7f8e562 | |
| ToppCell | Healthy-B_intermediate|World / disease group, cell group and cell class | 1.72e-04 | 195 | 25 | 3 | 9de79e0bdd9063ae65e5edb89cc3fe6f9a8173bc | |
| ToppCell | Bronchial-NucSeq-Stromal-Mesofibroblastic-Mesothelia|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.74e-04 | 196 | 25 | 3 | ce13af36fc2932e8125013041742593ff3d07e86 | |
| ToppCell | Bronchial-NucSeq-Stromal-Mesofibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.74e-04 | 196 | 25 | 3 | 96e5c6d155273e82ebafa180df8bb589c3e3e54e | |
| ToppCell | COVID-19-COVID-19_Severe-Myeloid-pDC|COVID-19_Severe / Disease, condition lineage and cell class | 1.80e-04 | 198 | 25 | 3 | 033ed362333e1d33f2aeea8da5865d2228d154dc | |
| ToppCell | MS-IIF-Myeloid-pDC|IIF / Disease, condition lineage and cell class | 1.82e-04 | 199 | 25 | 3 | e262ee854e64d87460bee810c14d6cbe744460e8 | |
| ToppCell | Bronchus_Control_(B.)-Stromal-TX-Fibroblasts-3|Bronchus_Control_(B.) / Sample group, Lineage and Cell type | 1.82e-04 | 199 | 25 | 3 | 07b8c33342c62afd9c63ec2d757cfa3ba65d2a98 | |
| ToppCell | COVID-19-COVID-19_Mild-Myeloid-pDC|COVID-19_Mild / Disease, condition lineage and cell class | 1.82e-04 | 199 | 25 | 3 | 9de61e5189d907cc969ac3043d68204f70acc0bf | |
| ToppCell | mLN-(5)_Dendritic_cell-(54)_pDC|mLN / shred on region, Cell_type, and subtype | 1.82e-04 | 199 | 25 | 3 | 1e738219784a446ee8b0ddeb408e0050e1929e60 | |
| ToppCell | mLN-Dendritic_cell-pDC|mLN / Region, Cell class and subclass | 1.82e-04 | 199 | 25 | 3 | 54f1abb57af7bf8a8b82a38b933f257df3b5d8df | |
| ToppCell | (54)_pDC|World / shred on Cell_type and subtype | 1.93e-04 | 203 | 25 | 3 | b8ba3e51770ff7b45cd02472f3e63aa4d5816f6f | |
| Drug | 3,5-heptanedione | 1.16e-05 | 5 | 25 | 2 | CID000081923 | |
| Drug | SAR 020106 | 2.42e-05 | 7 | 25 | 2 | ctd:C547874 | |
| Drug | 17-AAG; Down 200; 1uM; PC3; HT_HG-U133A | 5.29e-05 | 191 | 25 | 4 | 1225_DN | |
| Drug | Clindamycin hydrochloride [21462-39-5]; Up 200; 8.6uM; MCF7; HT_HG-U133A | 5.40e-05 | 192 | 25 | 4 | 2219_UP | |
| Drug | Enilconazole [35554-44-0]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 6.20e-05 | 199 | 25 | 4 | 5538_UP | |
| Drug | xestospongin C | 7.59e-05 | 12 | 25 | 2 | ctd:C511704 | |
| Disease | serine/threonine-protein kinase BRSK2 measurement | 2.07e-06 | 3 | 25 | 2 | EFO_0803063 | |
| Disease | major depressive episode, major depressive disorder | 4.03e-04 | 35 | 25 | 2 | EFO_0007634, MONDO_0002009 | |
| Disease | hepatocyte growth factor measurement | 6.38e-04 | 44 | 25 | 2 | EFO_0006903 | |
| Disease | major depressive episode | 7.28e-04 | 47 | 25 | 2 | EFO_0007634 | |
| Disease | neuroimaging measurement | 1.79e-03 | 1069 | 25 | 5 | EFO_0004346 | |
| Disease | mosaic loss of chromosome Y measurement | 2.09e-03 | 80 | 25 | 2 | EFO_0007783 | |
| Disease | alcohol drinking | 2.14e-03 | 81 | 25 | 2 | EFO_0004329 | |
| Disease | grip strength measurement | 3.14e-03 | 350 | 25 | 3 | EFO_0006941 | |
| Disease | 3-hydroxypropylmercapturic acid measurement | 3.19e-03 | 352 | 25 | 3 | EFO_0007014 | |
| Disease | Global developmental delay | 5.65e-03 | 133 | 25 | 2 | C0557874 | |
| Disease | Intellectual Disability | 6.20e-03 | 447 | 25 | 3 | C3714756 | |
| Disease | neurodegenerative disease (implicated_via_orthology) | 6.68e-03 | 145 | 25 | 2 | DOID:1289 (implicated_via_orthology) | |
| Disease | myeloid white cell count | 7.51e-03 | 937 | 25 | 4 | EFO_0007988 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| LLQHLGLEHYYPKKL | 861 | Q7Z2Y8 | |
| KHHYYGKKGIVSLLR | 2641 | Q9NYQ6 | |
| KLGYIGKLYHSHDLP | 256 | Q9UBM8 | |
| YPFELEKDLHLKGYH | 61 | Q9H649 | |
| YLHYKLKHEGPFKRK | 231 | Q8NFM7 | |
| PHVLKLHDVYENKKY | 76 | Q8IWQ3 | |
| HDPHLKAYYKRKDIL | 101 | Q5CZC0 | |
| LFKLGEPYHKKEHYL | 146 | Q9HCM2 | |
| YHLPSYLKLHDVLKA | 1231 | P42858 | |
| LLYIYGTHSHKLFKK | 21 | Q9HB55 | |
| YGYLKKYHIDLDPHF | 256 | P19784 | |
| PHVLKLHDVYENKKY | 91 | Q8TDC3 | |
| FKPYLKQHLPKRLHY | 421 | Q13822 | |
| LKFLRPHYGKLKEIY | 96 | Q13200 | |
| IDPALKKGHHKLYRY | 36 | Q9UPS6 | |
| KLPHFYKELYKEDLN | 256 | Q8NHU6 | |
| IHNAGPHRDKKLKYY | 276 | Q9NY97 | |
| KIFSDKDGYKHIHYI | 366 | Q12884 | |
| HKIIHTGEKPYKYEE | 206 | Q9UII5 | |
| LIAVLAKYIYHKHDP | 851 | Q5SRE5 | |
| PLKTPLFHSKYHYQK | 396 | O75326 | |
| YKKGFRKYLHLTEHL | 136 | Q494X3 | |
| YFYALRKHIKKDHPA | 1276 | Q96JM2 | |
| PILGYYLDKREVHHK | 741 | P54296 | |
| YKYKEGYRKQLGHHI | 3521 | P20929 |